Abstract
The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. 41 patients (median age 59 years) with MBC refractory or resistant to anthracyclines and taxanes were enrolled. The patients’ performance status (WHO) was 0 in 10 patients (24%), 1 in 22 (54%), and 2 in 9 (22%). 30 (73%) patients had received 2 or more prior chemotherapy regimens. Cyclophosphamide (600 mg m–2) was given i.v. bolus on day 1 and LV (500 mg m–2 d–1) as a 2-h infusion followed by 5-FU (1.5 g m–2 d–1) over a 22 h c.i. for 2 consecutive days. Cyclophosphamide was administered every 28 days while 5-FU/LV every 14 days. In an intention-to-treat analysis, complete response (CR) was achieved in 2 (4.9%) patients and partial response (PR) in 9 (22%) (overall response rate 26.9%; 95% CI: 13.27–40.39%). Stable disease (SD) and progressive disease (PD) were observed in 9 (22%) and 21 (51%) patients, respectively. The overall response rate was 6% and 40% in patients with primary and secondary resistance to anthracyclines/taxanes, respectively (P = 0.047). The median duration of response and the median time to disease progression was 8 and 9.5 months, respectively. The median overall survival was 13 months and the probability for 1-year survival 51%. Grade 3/4 neutropenia occurred in 9 (22%) patients and 4 (9%) patients developed grade 3/4 thrombocytopenia. Non-haematological toxicity was mild. There were no cases of febrile neutropenia, toxic deaths or treatment-related hospital admissions due to toxicity. The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients with MBC heavily pretreated with both anthracyclines and taxanes. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147–159
Borguez D, Vanhoefer U, Oberhoff C, Hense J, Mayer S, Bojko P, Harstrick A and Seeber S (2000) Phase I/II study of vinorelbine in combination with a weekly schedule of folinic acid and infusional 5-FU in patients with metastatic breast cancer (Abstract 420). Proc ASCO 14: 109a
Cameron DA, Gabra H and Leonard RC (1994) Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70, (1)120–124
Chang AY, Most C and Pandya KJ (1989) Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 12: 453–455
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi Danesi R, Innocenti F, Gentile A, Dell’Anna R, Biadi O, Mariani M and Del Tacca M (1997) Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510–2517
Cox DR (1970). The analysis of Binary Data. Methuen: London
Crivellari D, Magri DM, Buonadonna A, De Cicco M, Ferlante AM, Paolello C and Veronessi A (1999) Palliative treatment with 5-fluorouracil (FU) continuous infusion (ci) ± Navelbine (NVB) in metastatic, anthracycline refractory breast cancer (Abstract 436). Proc ASCO 18: 115a
Dogliotti L, Berruti A, Sperone P, Gorzegno G, Bottini A, Tampellini M, Donadio M and Alquati P (1999) Vinorelbine and protracted infusional 5-fluorouracil is a very active and manageable scheme for heavily pretreated advanced breast cancer patients (Abstract 432). Proc ASCO 18: 114a
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A and Martini C (1995) Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699
Gordon CJ, Valdivieso M, Martino S, Redman BG, Flaherty L and Baker LH (1990) Continuous intravenous 5-fluorouracil (5-FU), weekly adriamycin (ADR) and oral cyclophosphamide (CTX) (FAC-CT) in the treatment of metastatic breast carcinoma (MBC) (Abstract 200). Proc ASCO 9: 52
Hansen R, Quebbeman E, Beatty P, Ritch P, Anderson T, Jenkins D, Frick J and Ausman R (1987) Continuous 5-fluorouracil in refractory carcinoma of the breast. Breast Cancer Res Treat 10: 145–149
Jabboury K, Holmes FA and Hortobagyi G (1989) 5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793–797
Kaplan EL and Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA and Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A mid-Atlantic Oncology Program Study J Clin Oncol 7: 425–432
Mavroudis D, Malamos N, Alexopoulos A, Kouroussis Ch, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonikolis J, Kakolyris S, Samonis G and Georgoulias V (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Ann Oncol 10: 211–215
Monfardini S, Brunner K and Crowther D (1987) Evaluation of the cancer patient and the response to treatment. In UICC-Manual of Adult and Paediatric Medical Oncology (ed.) pp 22–38. Springer 1: Berlin
Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Bezwoda WR, Zaluski J, Pinter T, Krazakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A and Pouillart P (1999) A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC (Abstract 485). Proc ASCO 18: 127a
Piccart MJ, Raymond E, Aapro M, Eisenhauer EA and Cvitkovic E (1995) Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: Current status and future prospects. Eur J Cancer 31A, (7)1–10
Porkka K, Blomgvist C, Prissamen P, Elomaa I and Pyrhonen S (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. J Clin Oncol 12, (8)1639–1647
Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierma WA, Mortimer J, Genevois E and Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885 1
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kalbakis, K., Kouroussis, C., Kakolyris, S. et al. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. Br J Cancer 85, 798–802 (2001). https://doi.org/10.1054/bjoc.2001.2001
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2001
Keywords
This article is cited by
-
Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin
Breast Cancer Research and Treatment (2012)